Evidence map›Paper›PMID 38658952›Full record

ArticleJournal of nanobiotechnology2024

Drug repurposing-based nanoplatform via modulating autophagy to enhance chemo-phototherapy against colorectal cancer.

Ke Ding, Hailong Tian, Lei Li, Zhihan Wang, Shanshan Liu, Ning Ding, Edouard C Nice, Canhua Huang, Jinku Bao, Wei Gao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Ke Ding *Clinical Medical CollegeAffiliated Hospital of Chengdu University, Chengdu University, Chengdu, 610106, China.
Hailong Tian *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China, School of Basic Medical Sciences & Forensic Medicine, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China.
Lei Li *Department of anorectal surgery, Hospital of Chengdu University of Traditional Chinese Medicine and Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China.
Zhihan WangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China, School of Basic Medical Sciences & Forensic Medicine, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China.
Shanshan LiuDepartment of Clinical Pharmacy, School of Pharmacy, Zunyi Medical University, Zunyi, 563006, China.
Ning DingShanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Edouard C NiceDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, 3800, Australia.
Canhua HuangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China, School of Basic Medical Sciences & Forensic Medicine, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China.
Jinku BaoState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China, School of Basic Medical Sciences & Forensic Medicine, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China. baojinku@scu.edu.cn.
Wei GaoClinical Medical CollegeAffiliated Hospital of Chengdu University, Chengdu University, Chengdu, 610106, China. gaowei@cdu.edu.cn.
Zheng ShiClinical Medical CollegeAffiliated Hospital of Chengdu University, Chengdu University, Chengdu, 610106, China. drshiz1002@hotmail.com.
Chengdu University · CNSichuan University · CNState Key Laboratory of BiotherapyZunyi Medical University · CNChengdu University of Traditional Chinese Medicine · CNMonash University · AUShanghai University of Traditional Chinese Medicine · CN

Funding

Hospital level project of affiliated hospital of Chengdu University Y202232Innovation team project of Clinical Medical college & Affiliated hospital of Chengdu University CDFYCX202208Longquanyi Talents program No.90Quality of Talent Cultivation and Teaching Reform in Higher Education in Sichuan Province JG2021-1103Sichuan Provincial Youth Science and Technology Foundation 22NZZH0031
6 · The paper itself

Abstract

Multi-modal combination therapy is regarded as a promising approach to cancer treatment. Combining chemotherapy and phototherapy is an essential multi-modal combination therapy endeavor. Ivermectin (IVM) is a potent antiparasitic agent identified as having potential antitumor properties. However, the fact that it induces protective autophagy while killing tumor cells poses a challenge to its further application. IR780 iodide (IR780) is a near-infrared (NIR) dye with outstanding photothermal therapy (PTT) and photodynamic therapy (PDT) effects. However, the hydrophobicity, instability, and low tumor uptake of IR780 limit its clinical applications. Here, we have structurally modified IR780 with hydroxychloroquine, an autophagy inhibitor, to synthesize a novel compound H780. H780 and IVM can form H780-IVM nanoparticles (H-I NPs) via self-assembly. Using hyaluronic acid (HA) to modify the H-I NPs, a novel nano-delivery system HA/H780-IVM nanoparticles (HA/H-I NPs) was synthesized for chemotherapy-phototherapy of colorectal cancer (CRC). Under NIR laser irradiation, HA/H-I NPs effectively overcame the limitations of IR780 and IVM and exhibited potent cytotoxicity. In vitro and in vivo experiment results showed that HA/H-I NPs exhibited excellent anti-CRC effects. Therefore, our study provides a novel strategy for CRC treatment that could enhance chemo-phototherapy by modulating autophagy.

Indexed as

AutophagyColorectal NeoplasmsDrug RepositioningIvermectinNanoparticlesAnimalsAntineoplastic AgentsCell Line, TumorHumansHyaluronic AcidHydroxychloroquineIndolesMiceMice, Inbred BALB CMice, NudePhotochemotherapy2-(2-(2-chloro-3-((1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene)-1-cyclohexen-1-yl)ethenyl)-3,3-dimethyl-1-propylindoliumAntineoplastic AgentsHyaluronic AcidHydroxychloroquineIndolesIvermectinAutophagyChemo-phototherapyColorectal cancerDrug repurposing

Identifiers

PMID38658952
PMCPMC11040740
OpenAlexW4395081878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.